Eqis Capital Management, Inc. Ligand Pharmaceuticals Inc Transaction History

Eqis Capital Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$113.03 - $155.64 $152,929 - $210,580	-1,353 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$99.52 - $215.83 $134,650 - $292,017	1,353 New	1,353 $206,000
Q2 2019 Jul 18, 2019	SELL	$107.38 - $129.34 $340,931 - $410,654	-3,175 Closed	0 $0
Q1 2019 Apr 18, 2019	BUY	$105.93 - $142.47 $336,327 - $452,342	3,175 New	3,175 $399,000
Q2 2018 Jul 27, 2018	SELL	$150.77 - $207.98 $1.3 Million - $1.79 Million	-8,618 Closed	0 $0
Q1 2018 Apr 06, 2018	BUY	$138.63 - $182.62 $18,576 - $24,471	134 Added 1.58%	8,618 $1.42 Million
Q4 2017 Jan 25, 2018	BUY	$128.36 - $147.04 $34,528 - $39,553	269 Added 3.27%	8,484 $1.16 Million
Q3 2017 Oct 03, 2017	BUY	$120.91 - $137.94 $993,275 - $1.13 Million	8,215	8,215 $1.12 Million

256

18.1M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.94B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.